Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

Biotechnology Research

San Carlos, California 22,655 followers

Iovance is a patient-centric, collaborative organization that is driven to change the way cancer is treated.

About us

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings

Website
http://www.iovance.com/
Industry
Biotechnology Research
Company size
501-1,000 employees
Headquarters
San Carlos, California
Type
Public Company
Founded
2007
Specialties
Immuno Oncology, Autologous Cell Therapy, Tumor Infiltrating Lymphocytes (TIL), Novel Cancer Immunotherapies, and cell therapy

Locations

Employees at Iovance Biotherapeutics, Inc.

Updates

Similar pages

Browse jobs

Funding

Iovance Biotherapeutics, Inc. 8 total rounds

Last Round

Post IPO equity

US$ 211.0M

See more info on crunchbase